Fonar CORP 8-K filings

Fonar Corporation announced the completion of its merger with FONAR, LLC, resulting in its delisting from the Nasdaq Stock Market and a change in control.

FONAR Corporation stockholders have voted to approve the merger agreement with FONAR, LLC, with closing expected on June 3, 2026.

FONAR Corporation has filed supplemental disclosures regarding its pending going-private merger to address stockholder litigation.

FONAR Corporation announced its financial results for the third quarter and nine-month period of Fiscal Year 2026, reporting decreases in net income and income from operations.

FONAR Corporation announced its second-quarter fiscal 2026 financial results, showing revenue and net income growth for the quarter, alongside an increased take-private merger offer of $19.00 per share.

FONAR Corporation has entered into a definitive merger agreement to be acquired by an acquisition group led by its CEO for $90 million in cash, taking the company private.

FONAR Corporation reported a 4% increase in Q1 FY26 revenue to $26.0 million, but net income fell 33% to $2.7 million, while management continues negotiations for a potential going-private transaction.

FONAR Corporation announced its Fiscal 2025 financial results, showing a 1% revenue increase but significant declines in operating and net income, alongside continued growth in scan volume.

FONAR Corporation's Special Committee has received a supplemental proposal from a group led by CEO Timothy Damadian to acquire all outstanding shares not currently owned for $17.25 per share in cash, representing a 27% premium.

FONAR Corporation's Board of Directors has received a preliminary, non-binding proposal from a group led by CEO Timothy Damadian to acquire all outstanding capital stock not currently owned by the group at a premium of at least 10%.

FONAR Corporation announced the receipt of a preliminary, non-binding proposal from a group led by its CEO, Timothy Damadian, to acquire all outstanding capital stock not currently owned by the group at a premium of at least 10%.

FONAR Corporation announced the appointment of Robert M. Carrino, a Certified Public Accountant and partner at CFGI, as an independent director to its Board, filling a vacancy and bolstering the company's financial expertise as it transitions to accelerated filer status.

FONAR Corporation announced the retirement of Claudette J.V. Chan from its Board of Directors and as Secretary, effective June 19, 2025, with no reported disagreements.

FONAR Corporation held its annual meeting on May 19, 2025, electing five directors, approving executive compensation, and ratifying CohnReznick LLP as its auditor for the fiscal year ending June 30, 2025.

FONAR Corporation announces a 25% increase in net income to $3.1 million for the third quarter of fiscal year 2025, compared to the same period in the previous year.

FONAR Corporation announces its financial results for the second quarter and six-month period of fiscal year 2025, revealing a decrease in net income despite an increase in MRI scan volume at HMCA managed sites.

Fonar Corporation has dismissed Marcum LLP as its independent auditor and engaged CohnReznick LLP for the fiscal year ending June 30, 2025.

FONAR's first quarter of fiscal 2025 saw a 5% increase in MRI scan volume but a 3% decrease in total revenue and a 25% drop in net income compared to the same period last year.

FONAR Corporation announced a 16% increase in net income and an 11% increase in MRI scan volume for fiscal year 2024, driven by its diagnostic imaging management subsidiary, HMCA.

Fonar Corporation held its annual meeting on May 20, 2024, electing five directors, approving executive compensation, and ratifying the company's auditors.

FONAR Corporation announced a 25% increase in net income for the nine-month period ending March 31, 2024, driven by an 11% rise in MRI scan volume at HMCA-managed sites.

FONAR Corporation announced a significant increase in MRI scan volume, revenue, and net income for the second quarter and first six months of fiscal year 2024, driven by its diagnostic imaging management subsidiary, HMCA.